Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are: 1. To demonstrate that the combination of aliskiren / ramipril / amlodipine (300/10/10 mg) has superior efficacy compared to the combinations of ramipril / amlodipine (10/10 mg) in reducing MSSBP from baseline to the end of 12 weeks of treatment in patients with hypertension and metabolic syndrome not adequately responsive to amlodipine 10 mg. 2. To demonstrate that the combination of aliskiren / amlodipine (300/10 mg) has non-inferior efficacy compared to the combinations of ramipril / amlodipine (10/10 mg) in reducing MSSBP from baseline to the end of 12 weeks of treatment in patients with hypertension and metabolic syndrome not adequately responsive to amlodipine 10 mg.
Critère d'inclusion
- patients with essential hypertension and metabolic syndrome